🇺🇸 FDA
Patent

US 10251912

MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1

granted A61KA61K2039/53A61K2239/31

Quick answer

US patent 10251912 (MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Apr 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/53, A61K2239/31, A61K2239/38, A61K35/17